NewBioWorld A
Journal of Alumni Association of Biotechnology (2022) 4(2):18-24
REVIEW
ARTICLE
A Review on
various analytical methodology for Ondansetron
Ramniwas, Komal Gupta, Ankita Gupta, Aakanksha Sinha and
S.J. Daharwal*
University
Institute of Pharmacy Pt. Ravishankar Shukla University Raipur, Chhattisgarh, India
*Corresponding Author Email- daharwalresearch@rediffmail.com
ARTICLE INFORMATION
|
|
ABSTRACT
|
Article history:
Received
28 September 2022
Received in revised form
19 October 2022
Accepted
Keywords:
Ondansetron;
Analytical;
HPLC;
UV Spectroscopy;
HPTLC
|
|
The antiemetic drug ondansetron is used to treat nausea
and vomiting. the creation of a straight forward, quick, affordable,
accurate, and exact approach that has been approved for the estimation of
ondansetron in pharmaceutical dose form and bulk form. Whether ondansetron is being estimated in
pharmaceutical dose form or in bulk, the current study mostly focuses on
analytical methodologies and a few tested methods. Since they enable us to
employ cutting-edge analytical equipment to collect both qualitative and
quantitative data, analytical methods are crucial for determining
compositions. These methods aid in comprehending critical process factors and
reducing the detrimental influence they have on accuracy and precision.
Analytical technique development is required to uphold strict commercial
product quality standards and to comply with regulatory constraints. To
maintain high commercial product quality standards and to adhere to norms and
regulations, analytical technique development is necessary. Regulatory
organizations have created policies and procedures for granting
authorization, authentication, and registration in response to the reference.
|
|
1. Introduction
Ondansetron
was developed by Glaxo Smith Kline in 1980 and was given FDA approval in 1991.
This vital antiemetic medication is used to treat nausea and vomiting. The
medication is available as an intravenous injection, syrup, mouth dissolving
tablet, oral tablet, and capsule. The gastrointestinal tract is where
ondansetron is absorbed, and only a little amount of first-pass metabolism
occurs. It is a highly specialised and selective antagonist of the serotonin
5-HT3 receptor. Serotonin (5-HT) is released by enterochromaffin cells of the
small intestine in response to cytotoxic chemotherapy and radiotherapy, perhaps
causing vomiting. response by triggering the 5-HT3 receptors on the vagal
afferents. Ondansetron may prevent the reflex from starting. A central release
of serotonin from the region postrema's chemoreceptor trigger zone (Tramèr et
al. 1997), which is found on the fourth ventricle's floor, may also result from
the activation of vagal afferents. utilised to reduce vomiting and nausea by
lowering vagus nerve activity at the postrema chemoreceptor trigger zone. IUPAC
Name: 9-[(2-methylimidazol-1-yl)methyl]-3-[methyl]C18H19N3O is the chemical
formula for the compound -2, 3-dihydro-1H-carbazol-4-one (Tanveer et al. 2021).
1.1 Physicochemical properties of
ondansetron-
DOI: 10.52228/NBW-JAAB.2022-4-2-4
|
Ondansetron has the molecular formula C18H19N3O, is found as crystals,
and has a melting point between 231-232 °C. Ondansetron has a low solubility in
distilled water, a moderate solubility in acetate buffer, a moderate solubility
in a hydrochloric acid buffer with a pH of 2.8, and a moderate solubility in
ethanol (Suknuntha et al. 2022).
Figure 1: Structure of Ondansetron
1.2 Pharmacokinetics-
The
gastrointestinal tract is where ondansetron is absorbed, and only a little
amount of first-pass metabolism occurs. In comparison to the 8 mg tablet, the
16 mg tablets AUC was 24% greater. Ondansetron is a substrate of human hepatic
cytochrome P450 enzymes, including CYP1A2 and CYP2D6, according to
investigations on its in vitro metabolism. Ondansetron has been distributed in
an amount of 160L, according to records. Ondansetron is substantially metabolized
after being either orally or intravenously, and it is then eliminated in the
urine and faeces. Ondansetron clearance values in healthy adult volunteers aged
19 to 40. Ondansetron has a half-life of about 3–4 hours, while it can last up
to 6–8 hours in elderly patients (Roila et al.1995).
1.3 Pharmacodynamics-
The
serotonin 5-HT3 receptors are found centrally in the region postrema's
chemoreceptor trigger zone and peripherally on the vagus nerve terminals.
Serotonin is believed to be released from the enterochromaffin cells of the
small intestine by chemotherapeutic agents by inducing GI tract degeneration,
according to the temporal relationship between the emetogenic action of
emetogenic drugs and the release of serotonin as well as the effectiveness of
antiemetic medications. Serotonin activates the 5-HT3 receptors in the postrema
region and the vagal and splanchnic nerve receptors that project to the
medullary vomiting centre, triggering the vomiting reflex and resulting in
nausea and vomiting (Huddart et al. 2019). Negative outcomes are the most
frequently reported side effects include constipation, malaise, dry mouth,
headaches, and dry mouth. Local injection site reactions, pruritus, and central
nervous system (CNS) symptoms like weariness and drowsiness are among other
less common adverse effects. Pimozide and ondansetron shouldn't be given at the
same time since QTc prolongation can occur. Administration of amiodarone
together with ondansetron necessitates monitoring because it may also cause the
QTc interval to prolong. Serotonin syndrome may occur if ondansetron is taken
with other serotonergic medications (Stevens et al. 2017).
2.
Need of analytical method
For the
quality and development of formulations, quality assurance and quality control
departments in the pharmaceutical industry require analytically developed
methods. New analytical methods are more in demand because they are better at analyzing
and developing the good activity of drugs. The improved method also reduces
analysis time while increasing precision, accuracy, and analysis cost. The
analysis tools used in these procedures are essential for generating reliable
and high-quality data. These techniques could be electrochemical,
chromatographic, hyphenated, spectroscopic, or other. The creation of
analytical techniques helps to reduce the impact of key process variables on
precision and accuracy and to better understand them. Analytical methods should
be created utilizing the relevant procedures and requirements specified in the
ICH recommendations when following GMP and GLP regulations. Q2 (R1). The
process of choosing an exact assay technique to determine the composition of a
formulation is known as the analytical method, which is sometimes referred to
as the analytical approach. Analytical instrumentation must be carefully chosen
in order to develop a novel analytical process. Range, accuracy, precision,
linearity, limits of detection and quantitation (LOD), and specificity must all
be considered while developing a process (Ravisankar et al. 2014).
3. Analytical Method Development by UV
Spectroscopy: -
An
analytical method called UV spectroscopy counts the discrete wavelengths of UV
or visible light that a sample absorbs or transmits in comparison to a control
sample. Ultraviolet-visible spectroscopy is the study of interactions between
materials and electromagnetic radiation in this range. The ultraviolet region
has three wavelength ranges: UV-A (320-400 nm), UV-B (290-320 nm), and UV-C
(200-290 nm). According to the Beer- Lambert Law, a solution's absorbance and
its path length are exactly proportional to one another. In order to be able to
utilise it to determine the absorbance in a solution for a specific path length
(Anthony et al. 1993). A tungsten or halogen lamp is frequently used for
visible light in devices with two lights. Monochromators, absorption filters,
interference filters, cutoff filters, and band pass filters are some of the
available techniques (USP 2000). Examples of a few of those are given in Table
no. 2.
4. Analytical
method development by HPLC
High
performance liquid chromatography (HPLC) is by far the most widely used
sepration method and one of the most well-established analytical processes.
Using a liquid mobile phase, the components of a combination can be separated
using HPLC. A good silica and bonding method will result in a repeatable and
symmetrical peak, which is necessary for accurate certification. Commonly
utilized RP columns include C18 (USP L1), C8 (USP L8), phenyl (USP L11),
and cyno (USP L18). It is an analytical instrument that can
identify, classify, and quantify the drug, as well as its different
contaminants and drug-related degradation products that may occur during
manufacture or storage. The basic principle of HPLC in normal phase and reverse
phase mode is adsorption. The sample is introduced into HPLC column, different
components of the sample move according to their affinities towards the
stationary phase (Gupta et al. 2012, Sahu et al. 2018). Examples of a few
of those are given in Table no. 3.
5.
Analytical Method Development Using HPTLC Method
High
performance thin layer chromatography HPTLC is an automated form of thin layer
chromatography TLC based on separation of molecules by absorption. HPTLC
include phytochemical and biomedical analysis, herbal drug quantification,
active ingredient quantification, fingerprinting of formulations, and check for
adulterants in the formulations.
Selection of mobile phase is based on adsorbent material used as
stationary phase and physical and chemical properties of analyte. It has
increased reproducibility for quality control of herbal products by using standardized
methods and system suitability tests for the qualification of the plates. HPTLC
fingerprinting: Simplifying quality control, a single HPTLC study provides
information on the identification, purity, and content of an herbal drug,
preparation, or product (Patel et al. 2010). Examples of a few of
those are given in Table no. 4.
Table 1: Ondansetron brand name
along with drug formulation-
Drug
Formulation
|
Concentration
|
Route
of administration
|
Brand
Name
|
Tablet
|
8
mg
|
Orally
|
Zofran
|
Injection
|
2
mg
|
Intravenously
|
Ondansetron
injection-BP
|
Syrup
|
2
mg/5 ml
|
Orally
|
Vomikind
|
Solution
|
4
mg/5 ml
|
Orally
|
Ondansetron
|
Oral
suspension
|
1
mg/5 ml
|
Orally
|
R-Ondansetron
|
Mouth
dissolving tablet
|
4
mg
|
Sublingual
|
Ondet
|
Oral
drops
|
2
mg/5 ml
|
Orally
|
Zonda
|
Capsule
|
4/20
mg
|
Orally
|
OND-R
|
Table 2: Analytical
method development using UV- spectroscopy
S. No.
|
Sample
|
Method
|
Solvent
|
Wavelength
|
Linearity
|
Accuracy
|
Precision
|
LOD
|
LOQ
|
Reference
|
1
|
Tablet
|
Simultaneously
equation method
|
0.1 N HCL
|
261 nm
|
5-25 µg/ml
|
-
|
1.48
|
1.187 µg/ml
|
3.596
|
(Patra et al.
2017)
|
2
|
Tablet
|
Q- absorbance
ratio method
|
Methanol
|
260.6 nm
|
100-450 µg/ml
|
100.3
|
0.25
|
1.65 µg/ml
|
5 µg/ml
|
(Raza et al. 2007)
|
4
|
Bulk and
ointment
|
1st
order derivatives method (3092 double beam)
|
10% v/v
Ethanol
|
224.19 nm
|
17.5-32.5 µg/ml
|
99.89± 0.79
|
-
|
-
|
-
|
(Ravi Kumar
et al. 2006)
|
5
|
Tablet
|
1st
derivative spectra
|
0.01 M NaOH
|
246.0 nm
|
2-6 µg/ml
|
0.596± 0.0008
|
-
|
-
|
-
|
(Prasad et
al. 1989)
|
Table 3: Analytical method development
using HPLC method
S. No.
|
Dosage form
|
Stationary phase
|
Mobile phase
|
Wave-length
|
Flow rate
|
RT
|
linearity
|
Accuracy
(%)
|
Precision
(%)
|
LOD
|
LOQ
|
Reference
|
1
|
Tablet
IP
|
Column 25×4.6 mm
|
20:80 Acetonitrile and potassium
phosphate buffer solution respectively
|
216
nm
|
1.5
ml/min
|
1.0
min
|
-
|
-
|
-
|
-
|
-
|
(IP 2014)
|
2
|
Tablet
in bulk
|
C18 column (250 mm×4.6 mm id, 5µ
particle size)
|
Buffer: acetonitrile: Methanol (50:
40: 10 % v /v/v) (pH 4.5±0.05)
|
249
nm
|
1.0
ml/min
|
2.67±
0.05 min.
|
0.9982
|
100.45
|
<2
|
1.005
|
3.046
|
(Deshmukh et al. 2015)
|
3
|
Tablet
|
C18 (250 mm×4.6
mm, id 5µ particle size
|
50mm potassium dihydrogen orthophosphate:
acetonitrile (pH 6, ratio 60: 40 v/v)
|
222 nm
|
1.0
ml/min
|
6.4
min
|
0.992
|
-
|
0.70-1.82
|
-
|
-
|
(Meyyanathan et al. 2012)
|
4
|
Injectables
|
Inertsil
ODS 150×4.6 mm column with 3
|
70% KH 2 PO 4 20 mm with triethylammonium
phosphate and 30% acetonitrile
|
216 nm
|
1.5
ml/min
|
<2
min.
|
-
|
˂2
|
˂2
|
-
|
-
|
(Balint et al. 2018)
|
5
|
Tablet
|
C 18, 5µm, column (250×4.6mm)
|
methanol:
Acetonitrile: Potassium hydrogen ortho phosphate buffer pH 3 (40:20:40 v/v)
|
210 nm
|
1 ml/min
|
2.7
- 4.1 min
|
0.999
|
98-105
|
1.5
|
0.075
|
0.232
|
(Rakam et al. 2022)
|
Table 4: Analytical Method Development
Using HPTLC Method
S. No.
|
method
|
Sample
|
Stationary phase
|
Mobile phase
|
Wave length
|
Rf
|
Linearity
|
Accuracy
|
Precision
|
LOD
|
LOQ
|
Reference
|
1
|
HPTLC
|
Tablet
|
silica gel 60 F 254
|
Dichloromethane: Methanol (9:1)
|
309 nm
|
0.54± 0.03
|
100-500 ng/spot
|
-
|
-
|
99
|
302.8
|
(Raval et al. 2008)
|
2
|
HPTLC
|
Tablet
|
silica gel 60 F 254
|
Chloroform: methanol: ethyl
acetate (7:2:1 v/v).
|
302nm
|
0.67± 0.011
|
-
|
-
|
-
|
4.9
|
14.7
|
(Saraya et al. 2008)
|
3
|
HPTLC
|
Tablet
|
silica gel 60 F 254
|
toluene: methanol: acetone
(6:2:2.5, v/v/v)
|
286 nm
|
0.53
|
-
|
-
|
1.035
|
5.029
|
15.239
|
(Khatal et al. 2014)
|
4
|
HPTLC
|
Tablet in Bulk
|
silica gel 60 F254
|
Chloroform: ethyl acetate:
methanol: ammonia (9:5:4:0.1)
|
254 nm
|
0.52± 0.02
|
0.9952
|
-
|
-
|
14.83
|
44.92
|
(Mujtaba et al. 2013)
|
Conclusion
This
review article is based on the literature survey of the Estimation of ondansetron
with their various dosage form like tablet syrup injection by HPTLC, HPLC, UV
spectroscopy which include information regarding the drug ondansetron and its
analytical estimation through HPTLC, HPLC AND UV Spectroscopy. This analytical data
is useful for the development of new analytical method. The result of the article to give more
information about the drug ondansetron with the various analytical method uses
for the estimation of the drugs.
References
Anthony M, Sorkin EM
1993. Ondansetron an update of its therapeutic use in chemotherapy-induced and
post operative nausea and vomiting. Drugs; 45:931-52.
Balint, A., Silvia, I.M.R.E.,
Bondoroi-Papp, Z. and Muntean, D.L., 2018. Development of a new rp-hplc method
for ondansetron determination in injectable formulations. The Medical-Surgical
Journal, 122(1), pp.207-212.
Deshmukh, T.B., Deo,
S.S., Inam, F., Lambat, T.L., Gurubaxani, S.B. and Choudhari, A.V., 2015.
Development and validation of Ondansetron hydrochloride in pharmaceutical
dosage form by RP-HPLC method. Indian Journal of Advances in Science
Engineering and Technology, 1, pp.15-20.
Gupta, P.K., Ramisetti, N.R.,
Cecchi, T., Swain, S., Patro, C.S. and Panda, J., 2018. An overview of
experimental designs in HPLC method development and validation. Journal of Pharmaceutical
and Biomedical Analysis, 147, pp.590-611.
Gupta, V., Jain,
A.D.K.J., Gill, N.S. and Guptan, K., 2012. Development and validation of HPLC
method-a review. International Research Journal of Pharmaceutical and Applied
Sciences, 2(4), pp.17-25.
Huddart, R., Altman,
R.B. and Klein, T.E., 2019. PharmGKB summary: Ondansetron and tropisetron
pathways, pharmacokinetics and pharmacodynamics. Pharmacogenetics and Genomics, 29(4), p.91.
Khatal, L., More, H., Jadhav, A.,
Kuchekar, B., Dhaneshwar, S. And Polawar, A., 2014. Validated Hplc and Hptlc
Method for Simultaneous Quantitation of Ondansetron Hydrochloride and
Paracetamol in Bulk Drug and Formulation.
Meyyanathan, S.N., Venkatesh,
D.N., Krishnaveni, N., Babu, B., Jeyaprakash, M.R., Raja, R.B., Hemnath, E. and
Suresh, B., 2012. A RP-HPLC method for simultaneous estimation of ondansetron
and ranitidine in pharmaceutical formulation. International Journal of Health and
Allied Sciences, 1(2), p.129.
Mujtaba, A., Kohli, K., Ali, J.
and Baboota, S., 2013. Development of HPTLC method for the estimation of
ondansetron hydrochloride in bulk drug and sublingual tablets. Drug Testing and
Analysis, 5(2), pp.122-125.
Patel, R.B., Patel,
M.R., Bhatt, K.K. and Patel, B.G., 2010. HPTLC method development and
validation: quantification of paliperidone in formulations and in vitro release
study. Analytical Methods, 2(5), pp.525-531.
Patra S, Choudhury AA, Kar RK,
Barik BB. Spectrophotometric method for ondansetron hydrochloride. Indian J
Pharm Sci 2007; 69(6): 840-41. Edn, Merck and Company, Inc., pg. 1224.
Pharmacopeia, Indian. Vol. – 3
Indian Commission. Ghaziabad, Govt. of India: Ministry of Health and Family
Welfare, 2014: 2380-2381.
Prasad CVN, Parihar C, Sunil K and
Parimoop.P, 1989. Simultaneous determination of tinidazole- clotrimazole and
tinidazole- norfloxacin in combined tablet preparations with other drugs.
Journal of the association of official Analytical Chemists;72(3): 432-435.
Rakam, G.K., Mallik, A. and
Sucharitha, C., 2022. Method Development and Validation of Reverse Phase High
Performance Liquid Chromatography Method for Estimation of Ondansetron and
Pantoprazole in their Tablet Dosage Form. Indian Journal of Pharmaceutical
Sciences, 84(2), pp.483-192
Raval, P.B., Puranik, M., Wadher,
S.J. and Yeole, P.G., 2008. A validated HPTLC method for determination of
ondansetron in combination with omeprazole or rabeprazole in solid dosage form.
Indian Journal of Pharmaceutical Sciences, 70(3), p.386.
Ravi Kumar P, Murali Krishna M,
Bhanu prakash P, Anil kumar B and Madhusudhan P 2006. Derivative
Spectrophotometric Estimation of Ondansetron and Paracetamol. E-J Chem; 3(12):
134-36.
Ravisankar, P, Gowthami,
S and Rao, GD, 2014. A review on analytical method development. Indian
Journal of Research in Pharmacy and Biotechnology. ;2(3):1183.
Raza A, Ijaz AS, Atta-ur-Rehman,
Rasheed 2007. Spectrophotometric determination of ondansetron hydrochloride in
pharmaceutical bulk and dosage forms. J Chin Chem Soc; 54: 223-27.
Roila, F. and Del
Favero, A., 1995. Ondansetron clinical pharmacokinetics. Clinical
pharmacokinetics, 29(2), pp.95-109.
Saraya, R.E., Salam, R.A.A. and
Hadad, G.M., 2018. Stability-indicating high-performance thin-layer
chromatographic determination of ondansetron in pure form and pharmaceutical
formulations. JPC-Journal of Planar Chromatography-Modern TLC, 31(2),
pp.122-128.
Stevens, A.J., Woodman, R.J. and
Owen, H., 2015. The effect of ondansetron on the efficacy of postoperative
tramadol: a systematic review and meta‐analysis of a drug interaction.
Anaesthesia, 70(2), pp.209-218.
Suknuntha, K., Wattanapoka, K.,
Poonpattanachai, P., Titipornwanich, N. and Sripakdee, W., 2022. Compatibility
and Physical Properties of Dexamethasone-Ondansetron Intravenous Admixture. Hospital
Pharmacy, 57(5), pp.666-672.
Tanveer, S., Ahmad,
M., Minhas, M.U., Ahmad, A. and Khan, K.U., 2021. Chitosan-PVA-co-poly
(2-acrylamido-2-methylpropane sulfonic acid) cross-linked hybrid IPN-nanogels
for transdermal delivery of ondansetron; synthesis, characterization and
toxicological evaluation. Polymer-Plastics Technology and Materials, 60(17),
pp.1913-1934.
The United State Pharmacopoeia,
24 th ed. Philadelphia: National Publishing; 2000. p. 1218.
Tramèr, M.R., Moore, R.A.,
Reynolds, D.J.M. and McQuay, H.J., 1997. A quantitative systematic review of
ondansetron in treatment of established postoperative nausea and vomiting. BMJ,
314(7087), p.1088.